Skip to main content
Fig. 4 | Biomarker Research

Fig. 4

From: Integrative multi-omics analysis depicts the methylome and hydroxymethylome in recurrent bladder cancers and identifies biomarkers for predicting PD-L1 expression

Fig. 4

Utilizing 5mC biomarkers for predicting immunotherapy responses. A 5mC, 5hmC, and RRBS methylation level alternations in the TET gene. B The area under the curve (AUC) score for 5mC, 5hmC, and RRBS methylation in TET for predicting PD-L1 highly expressed bladder cancer. C Track plot showing the 5mC DMRs annotated to NFATC1 (left). The AUC score of one NFATC1 DMR for predicting PD-L1 highly expressed bladder cancer (right)

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us